Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Troy Asset Management Ltd increased its stake in Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 17.4% in the 4th quarter, ...

Shares in Vertex have soared after the company announced ... to move into phase 3 trials, and will form a three-way combination which could help 90% of patients of CF patients.

Annual Information Form for the year ended December 31, 2024, which may be accessed on Vertex's SEDAR+ profile at www.sedarplus.ca. The forward-looking statements contained in this Press Release ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...